AC
PHAT icon

Aristides Capital’s Phathom Pharmaceuticals PHAT Stock Holding History

Aristides Capital’s Portfolio PHAT Stock Details PHAT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-25,200
Closed -$205K – 310
2024
Q4 		$205K Buy
+25,200
New +$312K 0.04% 237

Other funds holding PHAT

FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
MVM
Medicxi Ventures Management St. Helier, Jersey $982M AUM 210.17% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
CG
Carlyle Group Washington, District of Columbia $10.6B AUM 11.25% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Ensign Peak Advisors
Ensign Peak Advisors Salt Lake City, Utah $53.7B AUM 29.47% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return

Aristides Capital's PHAT Position: Q1 2025 in Review

Aristides Capital sold out of Phathom Pharmaceuticals (PHAT) in Q1 2025, closing a stake of 25,200 shares — an estimated $205K sold.

Aristides Capital first reported a position in PHAT in Q4 2024 and held it in 1 quarter. The position peaked at $205K in Q4 2024. 137 funds tracked by Wall St. Rank hold PHAT as of Q1 2025.

  • Aristides Capital reported no remaining Phathom Pharmaceuticals position as of Q1 2025 after selling out during the quarter.
  • Aristides Capital sold 25,200 Phathom Pharmaceuticals shares in Q1 2025, an estimated $205K.
  • Aristides Capital first reported a position in Phathom Pharmaceuticals in Q4 2024 and held it in 1 quarter.
  • Aristides Capital's Phathom Pharmaceuticals position peaked at $205K in Q4 2024.
  • 137 funds tracked by Wall St. Rank held Phathom Pharmaceuticals as of Q1 2025.

Based on Aristides Capital's 13F filing for Q1 2025, filed 14 May 2025.